Steven Crouse Buys 20,000 Shares of OmniAb, Inc.
Insider Steven Crouse acquired 20,000 shares of OmniAb, Inc. on June 17, 2026.
Key Points
- Steven Crouse, an insider, bought 20,000 shares of OmniAb, Inc. on June 17, 2026.
- OmniAb, Inc. trades at $2.34 with a market cap of about $339.2 million and a 52-week range of $1.30 to $2.79.
- Institutional activity includes BlackRock, Inc. adding 41,900 shares, while Cadian Capital Management, LP reduced its stake by 277,825 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Steven Crouse, an insider, purchased 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). The transaction code was 'M', indicating a stock option exercise, and it wasn't part of a pre-planned trading program. The stock was trading at $2.34 at the time of the transaction.
Other Institutional Activity in OmniAb, Inc.
Several institutional investors have recently adjusted their positions in OmniAb, Inc. BlackRock, Inc. increased its holdings by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.7 million. Conversely, Cadian Capital Management, LP reduced its position by 277,825 shares, leaving it with 4,157,129 shares worth about $6.5 million. Geode Capital Management, LLC also boosted its stake by 202,887 shares, resulting in a total of 2,925,579 shares valued at $4.6 million.
OmniAb, Inc. Stock Down 47.7%
Shares of OmniAb, Inc. (NasdaqGM: OABI) are trading near $2.34. The company has a market capitalization of approximately $339.2 million and a beta of 1.146, indicating moderate volatility. Over the past year, the stock has ranged from a low of $1.30 to a high of $2.79. The 50-day moving average is $1.97, while the 200-day moving average is $1.80. OmniAb's liquidity is strong, with a current ratio of 4.80 and a quick ratio of 4.55, though it has a high debt-to-equity ratio of 7.49.
$OABI stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
OmniAb, Inc. reported revenue of $28.9 million, with a modest growth rate of 2.47%. However, the company is not currently profitable, with an EPS of -$0.46 and a negative net margin of -187.6%. Its return on equity stands at -20.25%. The next earnings release is scheduled for August 6, 2026.
Insider Buying and Selling at OmniAb, Inc.
In addition to Steven Crouse's purchase, several other insiders have been active. Jennifer Cochran and Carolyn Bertozzi each had multiple transactions on June 17, 2026. Cochran bought 40,000 shares and sold 20,000 shares, while Bertozzi purchased 60,000 shares and sold 20,000 shares. John Higgins also acquired 20,000 shares. None of these transactions were part of a pre-arranged trading plan.
Analysts Set New Price Targets
Analysts are optimistic about OmniAb, Inc.'s prospects. On March 19, 2025, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $11. Benchmark has also maintained a 'buy' rating, setting a target price of $6 as of May 12, 2025. Overall, the consensus target price is $7.33, based on six analyst opinions.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology firm based in Emeryville, California. The company specializes in licensing discovery research technology to pharmaceutical and biotech companies globally. OmniAb's platform uses biological intelligence to create optimized antibody candidates for therapeutic purposes. The company's technology includes genetically engineered animals like OmniRat and OmniChicken, designed to produce human-like antibodies for drug development.
Bottom Line
Steven Crouse's recent acquisition of OmniAb shares is part of a broader pattern of insider and institutional activity, reflecting ongoing interest in the company's prospects. Investors often track such transactions for insights into potential company performance. It's important to note that these filings reflect past actions and may not indicate current positions.
Get OmniAb, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OABI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.